Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2012

View Archived Issues

New immunoreactive protein leads to statistically significant decrease in E. muris bacterial load

Wnt signaling implicated in alopecia

Second germline SUFU mutation linked to Gorlin syndrome

Daiichi Sankyo presents in vitro and in vivo data for DS-7423

Chemokine CXCR7 receptor antagonist CCX-662 tested in glioblastoma model

Galapagos selects candidate drug from new class of antibiotics

Baylor College of Medicine presents new DNA vaccines

First-in-human trial of a new class of DNA repair inhibitors

Preclinical assessment of a novel bispecific antibody for the treatment of prostate cancer

New CDK8 inhibitors designed for the treatment of colorectal cancer

Janssen presents novel salts of a PDE10 inhibitor

Researchers at Galapagos disclose novel tyrosine-protein kinase inhibitors

New therapeutic nuclease compositions prepared at University of Washington

Sanofi patents novel P2Y12 receptor antagonists

Immune Design divulges new vaccines for HSV-2 infection

Bristol-Myers files for additional Hydrea indication in Japan

Chugai and Nippon Shinyaku agree on GA-101 development for NHL in Japan

Santen files for DE-114 approval in Japan

Meiji Seika Pharma launches Diacomit for Dravet syndrome in Japan

Oculus Innovative Sciences plans new subsidiary for anti-infective drug assets

MorphoSys and Lanthio Pharma agree to develop new class of therapeutic peptides

Isotechnika receives FDA clearance to commence phase III voclosporin trial

Adcetris receives FDA orphan drug designation for mycosis fungoides

Amitiza launched in Japan for chronic constipation

Prana completes enrollment in phase II trial of PBT-2 in Alzheimer's

New European approval for Humira in severe active pediatric Crohn's disease

Eylea for wet AMD approved in E.U., launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...